Unlike those digital notebooks, which are appealing because they lack traditional displays, the XP-Pen Magic Note Pad uses a ...
Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.
So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...
The U.K.’s National Institute for Health and Care Excellence on Thursday again denied to recommend Biogen and Eisai’s Alzheimer’s disease therapy Leqembi, noting that its clinical benefits do not ...
NEW YORK – The UK National Institute for Health and Care Excellence on Thursday issued two updated draft guidances recommending against making Eisai and Biogen's Leqembi (lecanemab) and Eli Lilly's ...
Associations between biomarkers of poor synapse health and higher levels of Alzheimer’s-related proteins in the brain, as well as steeper… The U.S. Food and Drug Administration (FDA) has approved ...
Good morning everyone, it’s Jason Mast, filling in for Ed. Today I’m in Pharmalittle’s New York bureau, sipping a cup poured from a French press gifted to me by my sisters, made from beans ...
"One Smart AI Pen", currently launched for crowdfunding on Kickstarter. | Credit: Zakwan Ahmad on Kickstarter On March 1st, engineer Zakwan Ahmad launched his concept for "The One Smart AI Pen" on ...
You may have seen the “Sell me that pen. It’s AI-powered” meme if you are a social media user. It may have started as a joke, but Zakwan Ahmad made the meme become reality with “The One Smart AI Pen” ...
Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...
In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the treatment of patients with Mild Cognitive Impairment (MCI) ...